From Wikipedia, the free encyclopedia
|
Lisuride
|
Systematic (IUPAC) name |
1,1-diethyl-3-((6aR,9S)-7-methyl-
-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinolin-9-yl)urea
|
Identifiers |
CAS number |
18016-80-3 |
ATC code |
G02CB02 N02CA07 |
PubChem |
28864 |
DrugBank |
APRD00636 |
Chemical data |
Formula |
C20H26N4O |
Mol. mass |
338.447 g/mol |
Pharmacokinetic data |
Bioavailability |
10-20% for lisuride hydrogenmaleate |
Protein binding |
about 15% |
Metabolism |
Hepatic |
Half life |
2 hours |
Excretion |
renal and biliary in equal amounts |
Therapeutic considerations |
Pregnancy cat. |
?
|
Legal status |
Prescription only
|
Routes |
Oral, subcutaneous, transdermal |
Lisuride (brand name in Germany Dopergin) is an anti-Parkinson's drug of the iso-ergoline class, chemically related to the dopaminergic ergoline Parkinson's drugs. Lisuride is described as free base (see table on the right) and as hydrogenmaleate salt.
Lisuride is used to lower prolactin and, in low doses, to prevent migraine attacks. The use of lisuride as initial anti-Parkinsonian treatment has been advocated, delaying the need for levodopa until lisuride becomes insufficient for controlling the Parkinsonian disability. Preliminary trials suggest that the dermal application of lisuride may be useful in the treatment of Parkinson's disease. Lisuride is not currently available in the US.
[edit] Mode of action
Lisuride is a dopamine agonist.
[edit] Commercial names
[edit] History
Synthesis of lisuride was first described in 1960.
[edit] Indications
[edit] See also
Ergolines |
|
Lysergic acid derivatives |
Bromocriptine, Cabergoline, Ergine, Ergonovine, Ergotamine, Lysergic acid, Lysergol, LSD, D-Lysergic acid hydroxyethylamide, Lisuride, Methergine, Methysergide, Pergolide
|
|
Hallucinogenic lysergamides |
AL-LAD, ALD-52, BU-LAD, CYP-LAD, DAL, DAM-57, Ergonovine, ETH-LAD, LAE-32, LSD, LPD-824, LSM-775, D-Lysergic acid N-(α-hydroxyethyl)amide, Methylergonovine, MLD-41, PARGY-LAD, PRO-LAD
|
|
Other ergolines |
|
|
Natural sources |
|
|